SEC Filing Document

Company: BIOVENTRIX, INC.
Ticker: 
CIK: 1283259
Filing Type: S-1/A
Document Type: S-1/A
Date Filed: 2026-05-15
Accession Number: 0001493152-26-023752
Exchange: 
SIC Code: 3841
SIC Description: Surgical & Medical Instruments & Apparatus
URL: https://www.sec.gov/Archives/edgar/data/1283259/000149315226023752/forms-1a.htm

Chunk 35 of 94
Word Count: 1339
Character Count: 8501

Document Content:

instruments, and U.S. government securities. addition, as a general matter, given our limited operating history, early stage of business and a new and unproven technology model, it is difficult to evaluate our business prospects and actual expenditures in the future. Further, our business plan will be very costly, far more costly than the net proceeds we will receive from this offering. To develop and implement our business as currently planned, we will need to raise substantial amounts of additional capital and we intend to raise such additional capital through public or private offerings of equity or equity-linked securities, traditional loans, commercial collaborations such as licenses or joint ventures and, if available or desirable, government funding, including grants. No assurances can be given that we will be able to raise additional capital when needed, and our inability to raise additional capital could lead to the failure of our company. DIVIDEND POLICY

have never declared or paid any cash dividends on our capital stock, and we do not anticipate paying any cash dividends in the foreseeable
future. The payment of dividends, if any, in the future is within the discretion of our board of directors and will depend on our earnings,
capital requirements and financial condition and other relevant facts. We currently intend to retain all future earnings, if any, to
finance the development and growth of our business.

CAPITALIZATION

The
following table sets forth our cash and equivalents and capitalization as of March 31, 2026:

an actual basis;

a pro forma basis to give effect to: the issuance of 7,943,927 shares of common stock upon the closing of this offering in
connection with the conversion of: (i) 1,302,950 shares of our existing Series A Preferred Stock into 1,302,950 shares
of common stock (assuming an initial public offering price of at least $10.00 and an assumed conversion price of $10.00) and (ii)
$12,797,898 of our existing convertible notes into 6,640,977 shares of our common stock (assuming an initial public
offering price of at least $10.00 and an assumed conversion price of $10.00); and

a pro forma as adjusted basis to give effect to: (i) our issuance and sale of              shares of our common stock in this offering at the
assumed initial public offering price of $              per share (the midpoint of the estimated price range set forth on the cover page of this
prospectus) and (ii) the deduction of $              of underwriting discounts and $              of estimated offering expenses payable by us, assuming the
underwriters do not exercise any portion of their over-allotment option.

The
information set forth in the table below is illustrative only and will be adjusted based on the actual initial public offering price
and other terms of this offering as determined at pricing. You should read this table together with “Management’s Discussion
and Analysis of Financial Condition and Results of Operations” and our audited financial statements and related notes and unaudited
interim condensed financial statements and related notes thereto included elsewhere in this prospectus.

As of March 31, 2026

Actual Pro Forma Pro
Forma As
Adjusted

Cash and cash equivalents $	924,026 $

Total liabilities 17,293,983

Stockholders’ Equity:

Preferred Stock: Par value of $0.0001 per share, 1,302,950 shares issued and outstanding, actual; par value of $0.0001
per share, no shares issued and outstanding, pro forma and pro forma as adjusted. 131

Common Stock: Par value of $0.0001 per share, 5,723,895 shares issued and outstanding, actual; par value of $0.0001 per
share, shares issued and outstanding, pro forma; par value of $0.0001 per share,           shares
issued and outstanding, pro forma as adjusted. 572

Additional paid-in capital 218,725,118

Accumulated deficit (234,498,143	)

Total stockholders’ equity (15,772,322	)

Total capitalization $	1,521,661 $

The
number of shares of our common stock to be outstanding upon completion of this offering will be              shares
assuming no exercise of the over-allotment by the underwriters, which is based on 5,723,865 shares of our common stock outstanding
as of March 31, 2026, and includes 7,943,927 shares of common stock being issued upon the closing of this offering
in connection with the conversion of: (i) 1,302,950 shares of our existing Series A Preferred Stock into 1,302,950 shares
of common stock (assuming an initial public offering price of at least $10.00 and an assumed conversion price of $10.00) and (ii) $12,797,898
of our existing convertible notes into 6,640,977 shares of our common stock (assuming an initial public offering price of at least
$10.00 and an assumed conversion price of $10.00), and excludes, as of the date of this prospectus:

●	shares of common stock issuable upon the exercise of the Underwriters’ Warrants;

shares of our common stock reserved for issuance under stock option agreements issued pursuant to the 2024 Plan; and

shares of our common stock (which is equal to         % of our issued and outstanding common
stock immediately after the consummation this offering) reserved for future issuance under the 2026 Plan, which will become effective
as of the closing of this offering.

Each
$1.00 increase (decrease) in the assumed initial public offering price of $        per share (the midpoint of the estimated price range set
forth on the cover page of this prospectus) would increase (decrease) the amount of cash, additional paid-in capital, total stockholders’
equity (deficit) and total capitalization on a pro forma as adjusted basis by approximately $          , assuming the number of shares, as set
forth on the cover page of this prospectus, remains the same and after deducting underwriting discounts and estimated offering expenses
payable by us. Similarly, each increase (decrease) of           shares offered by us would increase (decrease) cash, total stockholders’
equity (deficit) and total capitalization on a pro forma as adjusted basis by approximately $         , assuming the assumed initial public offering
price of $          per share (the midpoint of the estimated price range set forth on the cover page of this prospectus) remains the same, and
after deducting underwriting discounts and commissions and estimated offering expenses payable by us. The pro forma as adjusted information
discussed above is illustrative only and will be adjusted based on the actual public offering price and other terms of this offering
determined at pricing.

DILUTION

you purchase shares of our common stock in this offering, your interest will be diluted immediately to the extent of the difference between
the assumed initial public offering price of $          per share (the midpoint of the estimated
price range set forth on the cover page of this prospectus) and the pro forma as adjusted net tangible book value per share of our common
stock immediately upon the consummation of this offering. Net tangible book value per share of common stock is determined by dividing
our total tangible assets less total liabilities by the number of outstanding shares of our common stock. As of March 31, 2026,
we had a historical net tangible book value of $(15.8) million), or $(2.76) per share of common stock. Our historical net
tangible book value per share represented total tangible assets less total liabilities, divided by 5,723,865 shares of our common
stock outstanding as of March 31, 2026.

Our
pro forma net tangible book value as of March 31, 2026 was $        , or $
per share of our common stock based on         shares of our common stock outstanding. Pro forma
net tangible book value represents the amount of our historical total tangible assets less our total liabilities, after giving effect
to the issuance of         shares of common stock at a price of $ per share corresponding to
a financing that ended subsequent to            and the issuance of 7,943,927
shares of common stock being issued upon the closing of this offering in connection with the conversion of: (i) 1,302,950 shares
of our existing Series A Preferred Stock into 1,302,950 shares of common stock (assuming an initial public offering price of at
least $10.00 and an assumed conversion price of $10.00) and (ii) $12,797,898 of our existing convertible notes into 6,640,977
shares of our common stock (assuming an initial public offering price of at least $10.00 and an assumed conversion price of $10.00).